<DOC>
	<DOCNO>NCT01266954</DOCNO>
	<brief_summary>The purpose study explore potential dose response relationship pharmacokinetics GSK2141795 [ 18F ] FDG PET pharmacodynamic marker glucose metabolism tumor tissue . Three six subject enrol cohort dose repeat escalate dos GSK2141795 . [ 18F ] FDG PET image optional tumor biopsy do prior initiation dose sequentially select time point first five week dose . The maximal dose give schedule evaluate study exceed maximal tolerate dose establish first-time-in-human trial PCS112689 schedule .</brief_summary>
	<brief_title>An Open Label Study To Investigate Pharmacokinetics Pharmacodynamics Repeat Escalating Doses Oral AKT Inhibitor GSK2141795 18F FDG PET Analysis Subjects With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>1 . Capable give write informed consent 2 . Females nonchildbearing potential , 18 year old ovarian cancer 3 . Histologically cytologically confirm diagnosis PETpositive recurrent persistent ovarian cancer 4 . Histologically cytologically confirm diagnosis PETpositive recurrent persistent uterine gastrooesophageal tumor ( tumor type include poor enrollment patient ovarian cancer ) 5 . Disease least 2 cm suitable assessment image 6 . Performance Status score 0 , 1 2 accord Eastern Cooperative Oncology Group scale 7 . Adequate organ system function 1 . Chemotherapy , radiotherapy , immunotherapy within 28 day prior first dose GSK2141795 2 . Use investigational anticancer drug within 28 day five halflives , whichever short , prior first dose GSK2141795 3 . Current use prohibit medication 4 . Anticoagulants therapeutic dos permit consultation GSK Medical Monitor 5 . Presence active gastrointestinal disease condition could affect gastrointestinal absorption 6 . Any major surgery within last four week screen 7 . Unresolved toxicity great equal Grade 2 previous anticancer therapy 8 . Previously diagnose diabetes mellitus 9 . Current use oral corticosteroid , exception inhale topical corticosteroid 10 . Any serious unstable preexist medical , psychiatric , condition 11 . Symptomatic untreated CNS metastasis leptomeningeal involvement 12 . Evidence severe uncontrolled systemic disease 13 . QTc interval â‰¥ 470 msec 14 . Other clinically significant ECG abnormalities 15 . History myocardial infarction , acute coronary syndrome 16 . Class III IV heart failure 17 . Pregnant Lactating patient 18 . History hepatitis B C HIV</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>18F FDG</keyword>
	<keyword>PK</keyword>
	<keyword>PET</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>PD</keyword>
	<keyword>AKT Inhibitor</keyword>
	<keyword>GSK2141795</keyword>
</DOC>